I think one of the differences here is that rap is thinking...

I think one of the differences here is that rap is thinking bigger and trying to develop a broader application for use in diagnoses across a range of conditions. My understanding is that the ISN product is fairly niche as it is used to monitor specific asthmatic conditions once already diagnosed (and as you say it is a clunkier application with an external device). Good points about how the commercialisation is going to work here though...